

Contact

www.linkedin.com/in/jinfa-du-6123798 (LinkedIn)

Top Skills

Drug Development
Medicinal Chemistry
HPLC

Jinfa Du

Sr. Scientist II at Gilead Sciences
Pacifica, California, United States

Summary

Currently serves as Chairman, CEO&CSO of Geunune Biotech. Limited. Over 30 years of experience in discovery and development of drugs. Discovered and developed Azvudine as first oral antiviral agent against Covid-19 and marketed in China in July 25, 2022. He is expert particularly in discovery and development of nucleosides/tides based drugs for the treatment of cancers and infectious diseases, such as HIV and hepatitis B and hepatitis C infections. Project leader of nucleosides/tides research and associate director of chemical research in Pharmasset. Inventor and project leader of HCV drug Sofosbuvir (Sovaldi/Harvoni). Pharmasset was acquired by Gilead for \$11 billion in 2012. The total sales of Sovaldi/Harvoni was \$32 billions for first two years (2014+2015). Involved in the invention and development of clinical drugs including FTC (emtricitabine, Emtriva for HIV and HBV), Clevudine (L-FMAU, HBV drug approved in South Korea), DAPD (for HIV and HBV), Racivir, PSI-7851, and PSI-6130. Emtricitabine (FTC) has been one of important combination components in anti-HIV drugs, including most salable HIV drugs, such as Emtricitabine, Atripla, Complera, Truvada, and Stribild with total sales of \$10 billions/year. A co-inventor of 39 allowed US patents and 308 patent applications worldwide; published over 61 peer-reviewed articles; principal investigator of one NIH RO1 research grant and one small business grant.

Experience

真实生物

Chairman, CEO & CSO

January 2019 - Present (4 years 11 months)

中国 广东省 深圳

Gilead Sciences

Sr. Scientist II

January 2012 - October 2015 (3 years 10 months)

Page 1 of 2

Foster City, CA

Pharmasset

Sr. Principal Scientist

November 2005 - February 2012 (6 years 4 months)

Princeton, NJ

One of inventors of HCV drug, Sovaldi/Harvoni with sale of \$32 Billions in the first two years. Project Team Leader of nucleoside/tide research responsible for the discovery and development of nucleoside and nucleotide as antiviral drugs, in particular anti-HCV drugs, Sofosbuvir (Sovaldi/Harvoni or PSI-7977 or GS-7977).

Pharmasset, Inc.

Associate Director, Chemical Research

November 2001 - February 2005 (3 years 4 months)

PI of NIH RO1 research grant and one small business grant.

Triangle Pharmaceuticals

Sr Research Scientist

November 1998 - October 2001 (3 years)

Involved in development of HIV drug, Emtricitabine (FTC, Emtriva) which is also one of the drugs combined in the MOST salable HIV drugs, such as Truvada, Atripla and Stribild.

ICN Pharmaceuticals, Inc (Current Valent Pharmaceuticals, Inc)

Research Scientist

November 1997 - October 1998 (1 year)

Costa Mesa

Education

The University of Georgia

Ph.D., Medicinal chemistry · (1992 - 1997)

Peking Union Medical College

Doctor of Philosophy (Ph.D.), Medicinal and Pharmaceutical
Chemistry · (1984 - 1989)